The Most Read Articles of may in Interventional Cardiology

1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis

This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic patients.

Lea más AQUÍ

2- EuroPCR 2019 | Intravascular Imaging Almost Indispensable for Planning an Angioplasty

Cost and time are the two main enemies of intravascular imaging, but lack of expertise may also play a role. A new European Association of Percutaneous Cardiovascular Interventions (EAPCI) expert consensus statement released at EuroPCR 2019 argues that there is a need for more use of intracoronary imaging in settings of acute coronary syndromes and ambiguous coronary angiography findings, in order to guide interventions based on plaque characteristics.

Lea más AQUÍ

3- TAVR Still Gaining Ground Among Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has become the standard of care for patients with severe aortic stenosis and high surgical risk, and it should be considered as an option for intermediate-risk patients. In recent years, the number of low-risk patients treated with TAVR has increased. This study analyzes low-risk patients from the German Aortic Valve Registry (GARY) who underwent isolated TAVR vs. surgical treatment.

Lea más AQUÍ

4- EuroPCR 2019 | Most Recent TAVR Meta-Analysis: The Spectrum of Treatment Reaches All Patients

This new meta-analysis combines all randomized transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement trials and expands the scope of TAVR. Evidence across the range of risk studied supports a paradigm shift in patients with symptomatic severe aortic stenosis.

Lea más AQUÍ

5- EuroPCR 2019 | BASKET-SMALL 2: Drug-Coated Balloons vs. DES in Small Vessels

This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there were eight cases of stent thrombosis among drug-eluting stent (DES) patients, while there was none with drug-coated balloons.

Lea más AQUÍ

6- Latam SOLACI-EuroPCR Session

Once more, SOLACI is proud to participate at one of the most important interventional cardiology meetings in the world: the EuroPCR 2019.

Lea más AQUÍ

7- Staged Complete Revascularization vs. Culprit Vessel PCI at Long-Term

Staged complete revascularization in patients with acute myocardial infarction and multivessel coronary disease is superior to culprit PCI only at five-year follow-up. The outcomes of this retrospective analysis show the benefit of staged PCI, though it might be attenuated in diabetic patients. Outcomes are consistent with previously published randomized studies.

Lea más AQUÍ

8- Bolivia Sessions 2019: Clinical Case Contest for Young Interventional Cardiologists

It is with great pleasure that we hereby invite all young Latin American cardiologists to submit relevant clinical cases related to interventional cardiology for the upcoming SOLACI Sessions, Cochabamba 2019, to be held on August 23rd and 24th, 2019.

Lea más AQUÍ

9- Promising Results for Tricuspid Repair

Tricuspid regurgitation (TR) is more common than we thought. Around 1.6 million people in the US and over 3 million in Europe experience significant TR. It usually has a functional cause and its negative impact on patient prognosis is strong.

Lea más AQUÍ

10- EuroPCR 2019 | CHOICE: Balloon-Expandable Valves vs. Self-Expanding Valves in High-Risk Patients

The CHOICE trial included 241 patients with severe aortic stenosis and high surgical risk who underwent transcatheter aortic valve replacement (TAVR) using transfemoral access. These patients were randomized to balloon-expandable valve (Edwards Sapien XT) vs. self-expanding valve (Medtronic CoreValve). The endpoints were all-cause mortality, stroke, readmission, valve function parameters as measured through an ultrasound, and durability.

Lea más AQUÍ

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.